PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 37 filers reported holding PHARVARIS N V in Q2 2024. The put-call ratio across all filers is - and the average weighting 3.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $42,638 | -18.6% | 2,268 | 0.0% | 0.00% | – |
| Q1 2024 | $52,413 | -17.6% | 2,268 | 0.0% | 0.00% | – |
| Q4 2023 | $63,617 | +34.4% | 2,268 | 0.0% | 0.00% | – |
| Q3 2023 | $47,333 | +1903.9% | 2,268 | +1353.8% | 0.00% | – |
| Q2 2023 | $2,362 | +87.9% | 156 | 0.0% | 0.00% | – |
| Q1 2023 | $1,257 | -28.4% | 156 | 0.0% | 0.00% | – |
| Q4 2022 | $1,755 | +75.5% | 156 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -99.8% | 156 | -99.5% | 0.00% | – |
| Q2 2021 | $622,000 | -33.4% | 33,382 | 0.0% | 0.00% | – |
| Q1 2021 | $934,000 | – | 33,382 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 4,293,854 | $80,724,455 | 54.23% |
| venBio Partners LLC | 4,289,304 | $80,638,915 | 34.83% |
| Bain Capital Life Sciences Investors, LLC | 3,303,381 | $62,103,563 | 6.82% |
| GENERAL ATLANTIC, L.P. | 7,531,252 | $141,587,538 | 4.45% |
| VR Adviser, LLC | 3,395,606 | $63,837,393 | 4.06% |
| 5AM Venture Management, LLC | 797,600 | $14,994,880 | 3.35% |
| COMMODORE CAPITAL LP | 1,810,175 | $34,031,290 | 2.32% |
| Novo Holdings A/S | 1,725,000 | $32,430,000 | 1.88% |
| Cormorant Asset Management, LP | 1,466,460 | $27,569,448 | 1.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 403,265 | $7,581,382 | 1.03% |